As early detection is crucial for improvement of cancer prognosis, we searched for biomarkers in plasma from individuals who later developed squamous cell carcinoma of the oral tongue (SCCOT) as well as in patients with an already established SCCOT. Levels of 261 proteins related to inflammation and/or tumor processes were measured using the proximity extension assay (PEA) in 179 plasma samples (42 collected before diagnosis of SCCOT with 81 matched controls; 28 collected at diagnosis of SCCOT with 28 matched controls). Statistical modeling tools principal component analysis (PCA) and orthogonal partial least square - discriminant analysis (OPLS-DA) were applied to provide insights into separations between groups. PCA models failed to achieve group separation of SCCOT patients from controls based on protein levels in samples taken prior to diagnosis or at the time of diagnosis. For pre-diagnostic samples and their controls, no significant OPLS-DA model was identified. Potentials for separating pre-diagnostic samples collected up to five years before diagnosis (n = 15) from matched controls (n = 28) were seen in four proteins. For diagnostic samples and controls, the OPLS-DA model indicated that 21 proteins were important for group separation. TNF receptor associated factor 2 (TRAF2), decreased in pre-diagnostic plasma (< 5 years) but increased at diagnosis, was the only protein showing altered levels before and at diagnosis of SCCOT (p-value < 0.05). Taken together, changes in plasma protein profiles at diagnosis were evident, but not reliably detectable in pre-diagnostic samples taken before clinical signs of tumor development. Variation in protein levels during cancer development poses a challenge for the identification of biomarkers that could predict SCCOT development.

Department of Clinical Sciences Umeå University Umeå Sweden

Department of Medical Biosciences Umeå University Umeå Sweden

Research Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Brno Czechia

See more in PubMed

Williams SA, Kivimaki M, Langenberg C, Hingorani AD, Casas JP, Bouchard C, et al. . Plasma Protein Patterns as Comprehensive Indicators of Health. Nat Med (2019) 25(12):1851–7. doi: 10.1038/s41591-019-0665-2 PubMed DOI PMC

Landegren U, Hammond M. Cancer Diagnostics Based on Plasma Protein Biomarkers: Hard Times But Great Expectations. Mol Oncol (2020) 15(6):1715–26. doi: 10.1002/1878-0261.12809 PubMed DOI PMC

Suhre K, McCarthy MI, Schwenk JM. Genetics Meets Proteomics: Perspectives for Large Population-Based Studies. Nat Rev Genet (2021) 22(1):19–37. doi: 10.1038/s41576-020-0268-2 PubMed DOI

Fuzery AK, Levin J, Chan MM, Chan DW. Translation of Proteomic Biomarkers Into FDA Approved Cancer Diagnostics: Issues and Challenges. Clin Proteomics (2013) 10(1):13. doi: 10.1186/1559-0275-10-13 PubMed DOI PMC

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2018) 68(6):394–424. doi: 10.3322/caac.21492 PubMed DOI

SweHNCR . The Swedish Head and Neck Cancer Register. (2020). Available at: https://cancercentrum.se/globalassets/cancerdiagnoser/huvud-och-hals/kvalitetsregister/presentation-in-english-swehncr.pdf

Awan K. Oral Cancer: Early Detection is Crucial. J Int Oral Health (2014) 6(5):i–ii. PubMed PMC

Boldrup L, Troiano G, Gu X, Coates P, Fahraeus R, Wilms T, et al. . Evidence That Circulating Proteins are More Promising Than miRNAs for Identification of Patients With Squamous Cell Carcinoma of the Tongue. Oncotarget (2017) 8(61):103437–48. doi: 10.18632/oncotarget.21402 PubMed DOI PMC

Hussein AA, Forouzanfar T, Bloemena E, de Visscher J, Brakenhoff RH, Leemans CR, et al. . A Review of the Most Promising Biomarkers for Early Diagnosis and Prognosis Prediction of Tongue Squamous Cell Carcinoma. Br J Cancer (2018) 119(6):724–36. doi: 10.1038/s41416-018-0233-4 PubMed DOI PMC

Liu KYP, Lu XJD, Zhu YS, Le N, Kim H, Poh CF. Plasma-Derived Inflammatory Proteins Predict Oral Squamous Cell Carcinoma. Front Oncol (2018) 8:585. doi: 10.3389/fonc.2018.00585 PubMed DOI PMC

Boldrup L, Coates P, Gu X, Wang L, Fahraeus R, Wilms T, et al. . Low Potential of Circulating Interleukin 1 Receptor Antagonist as a Prediction Marker for Squamous Cell Carcinoma of the Head and Neck. J Oral Pathol Med (2021) 50(8):785–94. doi: 10.1111/jop.13187 PubMed DOI

Norberg M, Wall S, Boman K, Weinehall L. The Vasterbotten Intervention Programme: Background, Design and Implications. Glob Health Action (2010) 3:4643. doi: 10.3402/gha.v3i0.4643 PubMed DOI PMC

Wheelock AM, Wheelock CE. Trials and Tribulations of 'Omics Data Analysis: Assessing Quality of SIMCA-Based Multivariate Models Using Examples From Pulmonary Medicine. Mol Biosyst (2013) 9(11):2589–96. doi: 10.1039/c3mb70194h PubMed DOI

Spitzer M, Wildenhain J, Rappsilber J, Tyers M. BoxPlotR: A Web Tool for Generation of Box Plots. Nat Methods (2014) 11(2):121–2. doi: 10.1038/nmeth.2811 PubMed DOI PMC

Kong L, Birkeland AC. Liquid Biopsies in Head and Neck Cancer: Current State and Future Challenges. Cancers (Basel) (2021) 13(8). doi: 10.3390/cancers13081874 PubMed DOI PMC

Balkwill F. Tumour Necrosis Factor and Cancer. Nat Rev Cancer (2009) 9(5):361–71. doi: 10.1038/nrc2628 PubMed DOI

Borghi A, Verstrepen L, Beyaert R. TRAF2 Multitasking in TNF Receptor-Induced Signaling to NF-Kappab, MAP Kinases and Cell Death. Biochem Pharmacol (2016) 116:1–10. doi: 10.1016/j.bcp.2016.03.009 PubMed DOI

Shen RR, Zhou AY, Kim E, O'Connell JT, Hagerstrand D, Beroukhim R, et al. . TRAF2 is an NF-kappaB-Activating Oncogene in Epithelial Cancers. Oncogene (2015) 34(2):209–16. doi: 10.1038/onc.2013.543 PubMed DOI PMC

Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and Neck Squamous Cell Carcinoma. Nat Rev Dis Primers (2020) 6(1):92. doi: 10.1038/s41572-020-00224-3 PubMed DOI PMC

Ratna A, Mandrekar P. Alcohol and Cancer: Mechanisms and Therapies. Biomolecules (2017) 7(3). doi: 10.3390/biom7030061 PubMed DOI PMC

Chen X, Gole J, Gore A, He Q, Lu M, Min J, et al. . Non-Invasive Early Detection of Cancer Four Years Before Conventional Diagnosis Using a Blood Test. Nat Commun (2020) 11(1):3475. doi: 10.1038/s41467-020-17316-z PubMed DOI PMC

Jang J, Ma SH, Ko KP, Choi BY, Yoo KY, Park SK. Hepatocyte Growth Factor in Blood and Gastric Cancer Risk: A Nested Case-Control Study. Cancer Epidemiol Biomarkers Prev (2020) 29(2):470–6. doi: 10.1158/1055-9965.EPI-19-0436 PubMed DOI

Harlid S, Harbs J, Myte R, Brunius C, Gunter MJ, Palmqvist R, et al. . A Two-Tiered Targeted Proteomics Approach to Identify Pre-Diagnostic Biomarkers of Colorectal Cancer Risk. Sci Rep (2021) 11(1):5151. doi: 10.1038/s41598-021-83968-6 PubMed DOI PMC